04:22 AM EDT, 06/12/2025 (MT Newswires) -- Biogen (BIIB) and UCB said Thursday that additional results from a phase 3 study showed that dapirolizumab pegol led to "significant" improvements in disease activity for patients with moderate-to-severe systemic lupus erythematosus.

The study also showed improvements across additional clinical measures, including fatigue and disease activity/remission.

The companies said that dapirolizumab pegol's safety and efficacy in systemic lupus erythematosus have not been established, and it is not approved for use in the said indication by any global regulatory authority.

A second phase 3 trial of dapirolizumab pegol is ongoing with the target of confirming the results from the study, the companies said.

Systemic lupus erythematosus is a chronic, multifactorial autoimmune disease.